HCPLive Network

Multiple Sclerosis

An unexpectedly high number of cases of thrombotic microangiopathy has been reported in a small number of multiple sclerosis patients who are taking Rebif (interferon beta 1-alpha).
Researchers in the United Kingdom have shown a reduction in the rate of brain atrophy progression with use of 80-mg simvastatin daily in patients with secondary-progressive multiple sclerosis over a 2-year period.
Researchers at the National Institute of Neurological Disorders and Stroke may have found why patients taking the multiple sclerosis medication natalizumab (Tysabri) have a high risk of developing a rare brain infection that can be fatal.
Integrated clinical and specialty pharmacy practice model includes an interdisciplinary team of physicians, nurses, and pharmacists.
There has been an unusually high number of cases of thrombotic microangiopathy associated with severe or malignant hypertension in patients with multiple sclerosis who were receiving therapy with recombinant interferon beta, according to a letter to the editor published in the March 27 issue of the New England Journal of Medicine.
The American Academy of Neurology has released evidence-based recommendations for complementary and alternative medicine for multiple sclerosis. The guideline was published in the March 25 issue of Neurology.
Multiple Sclerosis Upcoming Events
Multiple Sclerosis Resources
$AD300x250BB$